Cambient Family Office LLC Buys Shares of 4,264 Novartis AG $NVS

Cambient Family Office LLC acquired a new position in shares of Novartis AG (NYSE:NVS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 4,264 shares of the company’s stock, valued at approximately $588,000.

Other institutional investors also recently bought and sold shares of the company. Fisher Asset Management LLC boosted its holdings in Novartis by 1.7% in the 3rd quarter. Fisher Asset Management LLC now owns 7,239,366 shares of the company’s stock worth $928,376,000 after buying an additional 117,952 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Novartis by 18.1% in the third quarter. JPMorgan Chase & Co. now owns 537,543 shares of the company’s stock worth $68,935,000 after acquiring an additional 82,226 shares during the last quarter. BXM Wealth LLC boosted its stake in shares of Novartis by 726.9% in the fourth quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock worth $5,903,000 after acquiring an additional 37,639 shares during the last quarter. Spire Wealth Management increased its position in shares of Novartis by 2,561.0% during the fourth quarter. Spire Wealth Management now owns 38,983 shares of the company’s stock worth $5,375,000 after purchasing an additional 37,518 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Novartis by 33.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,000 shares of the company’s stock worth $2,565,000 after purchasing an additional 5,000 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Argus raised Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Wednesday, March 11th. Weiss Ratings cut Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Sanford C. Bernstein raised Novartis to a “hold” rating in a report on Thursday, March 19th. Finally, Morgan Stanley lifted their price target on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research note on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Stock Performance

NYSE:NVS opened at $147.17 on Friday. The company has a market capitalization of $280.82 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 2.59 and a beta of 0.46. The business has a 50 day moving average of $149.10 and a 200 day moving average of $148.76. Novartis AG has a 1-year low of $112.34 and a 1-year high of $170.46. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65.

Novartis (NYSE:NVS) last released its quarterly earnings results on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). The business had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The company’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the company earned $2.28 EPS. On average, sell-side analysts predict that Novartis AG will post 8.82 earnings per share for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.